سعر باكتيريكس 1.5جم فيال 2026

Cefoperazone + sulbactam 1.5 g powder for injection, single vial for intramuscular or intravenous use; parenteral third-generation cephalosporin combined with a beta-lactamase inhibitor (Sigma, Egypt).

• Respiratory tract infections (upper and lower)Population: Adults and childrenPfizer Labeling (labeling.pfizer.com)
• Urinary tract infections (upper and lower)Population: Adults and childrenPfizer Labeling (labeling.pfizer.com)
• Peritonitis, cholecystitis, cholangitis and other intra-abdominal infectionsPopulation: Adults and childrenPfizer Labeling (labeling.pfizer.com)

• Very common: neutropenia, leucopenia, positive direct Coombs test, decreased haemoglobin/haematocrit, thrombocytopenia and raised ALT, AST and alkaline phosphatase. Common: coagulopathy, eosinophilia, diarrhoea, nausea, vomiting, raised bilirubin. Uncommon: headache, pruritus, urticaria, infusion-site phlebitis, injection-site pain, pyrexia, chills.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)
• Frequency not known (mainly post-marketing): anaphylactic shock/reactions (fatalities reported), hypoprothrombinaemia, haemorrhage (including fatal), vasculitis, hypotension, pseudomembranous colitis, jaundice, toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, maculopapular rash and haematuria.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)

• Hypersensitivity to sulbactam, cefoperazone, other beta-lactams or any excipient.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)

• Serious, occasionally fatal anaphylactic reactions have been reported with beta-lactams including sulbactam/cefoperazone; ask about previous hypersensitivity to cephalosporins, penicillins or other drugs; stop the drug and give emergency treatment (epinephrine, oxygen, IV steroids, airway management) as needed.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)
• Severe, occasionally fatal skin reactions (toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis) have been reported; discontinue if a severe skin reaction occurs.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)
• Haemorrhage, sometimes fatal, and vitamin K deficiency with coagulopathy have been reported, particularly with poor diet, malabsorption, prolonged intravenous alimentation or oral anticoagulants; monitor prothrombin time/INR in these patients, give vitamin K as indicated and discontinue if persistent bleeding has no other explanation.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)

• Alcohol (including ethanol-containing feeding solutions)Flushing, sweating, headache and tachycardia have been reported with alcohol taken during and up to the fifth day after cefoperazone; avoid alcoholic beverages and ethanol-containing oral or parenteral feeding solutions.Pfizer Labeling (labeling.pfizer.com)
• AminoglycosidesPhysically incompatible when mixed directly; when used together monitor renal function during therapy.Pfizer Labeling (labeling.pfizer.com)
• Oral anticoagulantsPatients on oral anticoagulants are at risk of bleeding/hypoprothrombinaemia; monitor prothrombin time/INR and give vitamin K as indicated.Pfizer Labeling (labeling.pfizer.com)

• Rat reproduction studies at up to 10 times the human dose showed no impaired fertility or teratogenicity; sulbactam and cefoperazone cross the placenta; no adequate well-controlled studies in pregnant women, so use during pregnancy only if clearly needed.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)
• Only small quantities of sulbactam and cefoperazone are excreted in human milk; use with caution in nursing mothers.International label, equivalent formulation · Pfizer Labeling (labeling.pfizer.com)

• Cefoperazone: Semisynthetic broad-spectrum third-generation cephalosporin that inhibits bacterial cell-wall synthesis; extensively excreted in bile.
• Sulbactam: Irreversible beta-lactamase inhibitor (a penicillanic acid sulfone) that protects cefoperazone from hydrolysis by many beta-lactamases.